NDC-11 (Package) | NDC-9 (Product) | Generic Name (Descending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
30698-0201-30 | 30698-0201 | Bromocriptine Mesylate | Parlodel | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | April 28, 2014 | In Use | |
30698-0202-01 | 30698-0202 | Bromocriptine Mesylate | Parlodel | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | April 28, 2014 | In Use | |
30698-0202-30 | 30698-0202 | Bromocriptine Mesylate | Parlodel | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | April 28, 2014 | In Use | |
60687-0286-11 | 60687-0286 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | July 7, 2017 | In Use | |
60687-0286-21 | 60687-0286 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | July 27, 2017 | Sept. 30, 2024 | In Use |
76189-0113-18 | 76189-0113 | Brigatinib | Alunbrig | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1/ EGFR | Oral | April 28, 2017 | Dec. 12, 2020 | No Longer Used |
76189-0113-21 | 76189-0113 | Brigatinib | Alunbrig | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1/ EGFR | Oral | April 28, 2017 | Dec. 12, 2020 | No Longer Used |
51144-0050-01 | 51144-0050 | Brentuximab vedotin | Adcetris | 50.0 mg/10.5mL | Immunotherapy | Drug Antibody Conjugate | CD30 | Intravenous | Aug. 25, 2011 | In Use | |
63539-0117-01 | 63539-0117 | Bosutinib monohydrate, Bosutinib | Bosulif | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 4, 2012 | In Use | |
00069-0135-01 | 00069-0135 | Bosutinib monohydrate | Bosulif | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 4, 2012 | In Use |
Found 10,000 results in 10 milliseconds — Export these results